Featured Story | By Nick Paul Taylor Endo International’s attempt to use ultrasound-guided injection of collagenase clostridium histolyticum to treat frozen shoulder has come unstuck. The drug, the active ingredient in the approved Xiaflex, failed to beat placebo in a phase 2 clinical trial, driving Endo to reevaluate its plans in the indication. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Cerebral Therapeutics has secured cash to get its implanted infusion epilepsy treatment ready for phase 3 development. Lynx1 Capital Management led the series C round, joining with VCs including RA Capital Management and Perceptive Advisors to give Cerebral $40 million to wrap up a midphase study. read more By Nick Paul Taylor Iveric Bio has struck a deal to switch up the delivery profile of its age-related macular degeneration prospect Zimura. With phase 3 data on the current formulation due soon, the retinal disease biotech has partnered with DelSiTech to develop a sustained-release successor. read more By Nick Paul Taylor Avacta has cleared another small hurdle in its race to provide an improved doxorubicin using its delivery platform. The safety data monitoring committee gave the thumbs-up to Avacta after reviewing data from the second dose cohort, clearing the company to step up to the next level. read more By Gabrielle Masson ReCode Therapeutics has stuck to a formula of $80 million funding rounds, but thanks to investments from the venture arms of Bayer and Amgen, the genetic medicine and mRNA biotech is breaking the mold with a $120 million extended series B. read more By Teresa Carey This week on "The Top Line," we discuss what FDA advisors want added to future COVID vaccine doses—and why. Also, experts predict an uptick in dealmaking, particularly for a few key companies. read more Resources Sponsored by: Cognizant Explore how Cognizant SIP helped Roche streamline its global feasibility process. Sponsored by: Blue Matter Consulting For an emerging biopharma company, Europe can be very attractive. But it can also be complex and confusing. This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Thermo Fisher Scientific Sponsored by Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: CG Life Explore the new cell therapy handbook from Thermo Fisher Scientific. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? | 
